Cetirizine Tablet Recall: Rising Pharma Lot PY925014, PY925013
Announced 2026-07-29 · FDA
FDA is recalling Cetirizine Hydrochloride Tablets USP due to imprint with an incorrect ID. About 13,440 bottles distributed nationwide are affected. Lot numbers PY925014 and PY925013 expire 1/31/2028; manufactured by Unique Pharmaceuticals Labs and distributed by Rising Pharma Holdings.
| Brand | JB Chemicals and Pharmaceuticals Ltd |
|---|---|
| Product | Cetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-50 |
| Reason | Tablet/Capsules Imprinted with Wrong ID |
| Severity | low |
| Units affected | 34020 |
| Distribution | U.S. Nationwide |
| Agency | FDA |
| Recall / campaign no. | Lot # PY925014, PY925013, Exp. 1/31/2028 |
WHAT YOU SHOULD DO
- Check your bottle for Lot PY925014 or PY925013 and stop using it if found.
- Return or discard affected bottles according to the recall instructions from Rising Pharma Holdings.
- If you have taken the product, contact your healthcare provider for advice.
- For more information, monitor FDA recall notices or contact the distributor/manufacturer listed.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.